This Plain Language Summary of Publication article (PLSP) from Future Oncology, the EV-302/KEYNOTE-A39 study evaluated enfortumab vedotin (EV) combined with pembrolizumab as a potential treatment for advanced urothelial cancer. Researchers compared this combination to standard platinum-based chemotherapy, which may not always be effective and can cause significant side effects. The study aimed to determine if EV with pembrolizumab provided better outcomes for patients.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer’ and was published in the New England Journal of Medicine.

Visit NEJM using the link to read the original article.